Search

Contact Us

Author: admin

Published by

Webinar presented by Integral Molecular and Fierce Biotech – Conquering Undruggable Targets to Obtain Preclinical Antibodies

Thursday, September 14, 2023 8 am PT, 11 am ET, 17:00 CET Watch the webinar Despite the remarkable growth of antibody-based therapies in recent […]

Read More

Published by

Integral Molecular Awarded $1 Million by Commonwealth of Pennsylvania to Support Biotechnology Pandemic Research Center

PHILADELPHIA–Integral Molecular is proud to announce that the Commonwealth of Pennsylvania has awarded the company $1M of funding through the Redevelopment Assistance Capital Program […]

Read More

Published by

A Shot in the Arm for Flu Research: Integral Molecular Introduces Off-the-Shelf Reagents to Evaluate 2023/2024 Influenza Vaccine Efficacy

PHILADELPHIA–Integral Molecular, a leader in providing safe, off-the-shelf Reporter Virus Particles (RVPs) to study vaccine efficacy, has expanded its extensive portfolio with RVPs for […]

Read More

Published by

Genetic Engineering and Integral Molecular Present – Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array

  Thursday, June 22, 2023 Watch the webinar Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, […]

Read More

Published by

Integral Molecular Opens New Research Center in Philadelphia Encompassing Pandemic Preparedness Laboratories

PHILADELPHIA–Integral Molecular, a founding member of Philadelphia’s biotech community, announces the official opening of its 32,000 square foot headquarters and integrated research facilities that […]

Read More

Published by

Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors

PHILADELPHIA–Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) […]

Read More

Published by

Integral Molecular Partnership: Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December […]

Read More

Published by

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

PHILADELPHIA–Using its extensive experience gained fighting COVID-19 and other virus threats for over 20 years, Integral Molecular has launched an expanded collection of its […]

Read More

Published by

Genetic Engineering and Integral Molecular Present – Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic

  Thursday, November 10, 2022 Watch the webinar The COVID-19 pandemic has brought virology to the forefront of many research programs. But how do […]

Read More

Search